ライフサイエンスコーパス: acute gout

1 sting is necessary in patients with possible acute gout.

2 analgesic effectiveness among patients with acute gout.

3 corticosteroids relieve pain in adults with acute gout.

4 corticosteroids reduce pain in patients with acute gout.

5 effective first-line option for treatment of acute gout.

6 inhibitors and glucocorticoids for treating acute gout.

7 well as traditional NSAIDs, are effective in acute gout.

8 s confirmed to be an effective treatment for acute gout.

9 ptomatic hyperuricemia and the resolution of acute gout.

10 corticosteroids reduce pain in patients with acute gout.

11 tained regarding the inflammatory process in acute gout.

12 ess the role of CXCR-2 ligands in a model of acute gout.

13 trophil-dependent inflammation is central to acute gout.

14 SAIDs), or colchicine to treat patients with acute gout.

15 corticosteroids relieve pain in adults with acute gout.

16 se colchicine when using colchicine to treat acute gout.

17 -1 inhibitors or placebo in the treatment of acute gout?

18 se reductions of 33-66% for the treatment of acute gout and 50-75% for prophylaxis were calculated fo

19 Because acute gout and pseudogout appear to be dependent on inte

20 yrophosphate dihydrate (CPPD) crystals cause acute gout and pseudogout, respectively.

21 eroids are increasingly accepted in treating acute gout, and the role of colchicine in acute and inte

22 Rate of recurrent acute gout, ascertained by hospitalization, outpatient,

23 ol or febuxostat) reduces long-term risk for acute gout attacks after 1 year or more.

24 ly colchicine or NSAIDs reduces the risk for acute gout attacks by at least half in patients starting

25 Although acute gout attacks can be treated, eliminating gout requ

26 rpose: To review evidence about treatment of acute gout attacks, management of hyperuricemia to preve

27 To review evidence about treatment of acute gout attacks, management of hyperuricemia to preve

28 ases serum urate levels and reduces risk for acute gout attacks.

29 that is used in prophylaxis and treatment of acute gout flare, alleviates the painful inflammatory re

30 Of these, 1679 acute gout flares (95%) occurred in people with baseline

31 nted on appropriate dosing of colchicine for acute gout flares and potential toxicities of combining

32 Rates of acute gout flares per 1000 person-years were 10.6 for pa

33 ng the promise of the drug anakinra to treat acute gout flares.

34 vents of clinically relevant hyperuricaemia (acute gout, gouty arthritis or initiation of anti-gout t

35 o play a key role in the resolution phase of acute gout has also been demonstrated.

36 important in controlling the development of acute gout in patients with hyperuricemia.

37 e anti-inflammatory effects of colchicine in acute gout-like inflammation can be accounted for by inh

38 Unlike IL-8, the roles in acute gout of individual complement-derived peptides and

39 Acute gout patients showed elevated concentration of PTX

40 is for oral colchicine therapy and dosing in acute gout remains limited.

41 investigated both for the management of the acute gout symptoms, targeting interleukin-1beta, as wel

42 Limitation: Few studies of acute gout treatments, no placebo-controlled trials of m